Oragenics Partners with Receptor.AI to Accelerate AI-Driven Discovery of Brain-Targeted Therapeutics

Oragenics Inc. (NYSE American: OGEN), a clinical-stage biotechnology company advancing brain-targeted therapies through proprietary intranasal delivery technology, has announced a strategic collaboration with Receptor.AI to accelerate the development of new drug candidates for neurological conditions. The partnership represents a significant step in the company's evolution beyond its lead concussion candidate, ONP-002, toward becoming a diversified neurological therapeutics developer.

The collaboration will apply AI-based receptor modeling to optimize binding profiles for compounds Oragenics acquired in 2023. This approach aims to streamline preclinical discovery and enhance capital efficiency by combining artificial intelligence with the company's precision intranasal delivery technology. CEO Janet Huffman emphasized that this partnership underscores the company's strategic direction toward leveraging advanced technologies to address complex neurological challenges.

Oragenics' proprietary intranasal delivery technology has the potential to enable targeted, non-invasive therapeutics for brain-related conditions. While ONP-002 continues to advance as a potential first FDA-approved treatment for concussion, the company's platform technology shows promise for addressing broader neurological applications including neurodegenerative diseases and CNS disorders. The full details of the partnership announcement are available at https://ibn.fm/Wo8YZ.

The collaboration with Receptor.AI represents a growing trend in the pharmaceutical industry where traditional drug development approaches are being augmented by artificial intelligence and computational methods. By applying AI-based receptor modeling to existing compound libraries, Oragenics aims to identify and optimize promising candidates more efficiently than through conventional screening methods alone. This approach could potentially shorten development timelines and reduce costs associated with bringing new neurological treatments to market.

Investors and stakeholders can access additional company information through Oragenics' newsroom at https://ibn.fm/OGEN. The partnership announcement was distributed through InvestorWire, a specialized communications platform that provides wire-grade press release syndication services as part of the Dynamic Brand Portfolio. The platform offers advanced distribution capabilities including article syndication to over 5,000 outlets and social media distribution to millions of followers, though the company's focus remains on the scientific and therapeutic implications of this AI-driven collaboration.